Akt Inhibitor MK2206

Search with Google Search with Bing

Information
Drug Name
Akt Inhibitor MK2206
Description
Entry(CIViC)
7
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
skin melanoma PTEN p.Thr319Ter (p.T319*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) PTEN p.Thr319Ter (p.T319*)
( ENST00000713839.1, ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2 ) 		D Predictive Supports Sensitivity/Response Somatic 3 24504448 Detail
ovarian serous cystadenocarcinoma CCNE1 AMPLIFICATION
( ENST00000262643.8 ) CCNE1 AMPLIFICATION
( ENST00000262643.8 ) 		D Predictive Supports Sensitivity/Response Somatic 4 27663592 Detail
breast cancer AKT3 OVEREXPRESSION AKT3 OVEREXPRESSION D Predictive Supports Resistance N/A 4 27297869 Detail
breast cancer AKT1 p.Glu17Lys (p.E17K)
( ENST00000402615.6, ENST00000349310.7, ENST00000554848.5, ENST00000555528.5, ENST00000407796.7, ENST00000553797.2, ENST00000554192.6, ENST00000554581.5, ENST00000555458.6, ENST00000649815.2, ENST00000683722.1, ENST00000714123.1, ENST00000714130.1 ) AKT1 p.Glu17Lys (p.E17K)
( ENST00000349310.7, ENST00000402615.6, ENST00000407796.7, ENST00000553797.2, ENST00000554192.6, ENST00000554581.5, ENST00000554848.5, ENST00000555458.6, ENST00000555528.5, ENST00000649815.2, ENST00000683722.1, ENST00000714123.1, ENST00000714130.1 ) 		D Predictive Does Not Support Sensitivity/Response Somatic 3 23888070 Detail
breast cancer PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 23888070 Detail
pancreatic carcinoma KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		C Predictive Supports Sensitivity/Response Somatic 2 22025163 Detail
pancreatic carcinoma PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		C Predictive Supports Sensitivity/Response Somatic 2 22025163 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
A 26-year old patient presented with vemurafenib r... PTEN PTEN p.Thr319Ter (p.T319*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) PTEN p.Thr319Ter (p.T319*)
( ENST00000713839.1, ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2 ) 		Sensitivity true CIViC Evidence detail
A high throughput compound screen identified syner... CCNE1 CCNE1 AMPLIFICATION
( ENST00000262643.8 ) CCNE1 AMPLIFICATION
( ENST00000262643.8 ) 		Sensitivity true CIViC Evidence detail
Upregulation of AKT3 due to epigenetic reprogrammi... AKT3 AKT3 OVEREXPRESSION AKT3 OVEREXPRESSION Resitance or Non-Reponse true CIViC Evidence detail
Breast cancer cell lines with the AKT1 E17K mutati... AKT1 AKT1 p.Glu17Lys (p.E17K)
( ENST00000402615.6, ENST00000349310.7, ENST00000554848.5, ENST00000555528.5, ENST00000407796.7, ENST00000553797.2, ENST00000554192.6, ENST00000554581.5, ENST00000555458.6, ENST00000649815.2, ENST00000683722.1, ENST00000714123.1, ENST00000714130.1 ) AKT1 p.Glu17Lys (p.E17K)
( ENST00000349310.7, ENST00000402615.6, ENST00000407796.7, ENST00000553797.2, ENST00000554192.6, ENST00000554581.5, ENST00000554848.5, ENST00000555458.6, ENST00000555528.5, ENST00000649815.2, ENST00000683722.1, ENST00000714123.1, ENST00000714130.1 ) 		Sensitivity false CIViC Evidence detail
PIK3CA E545K mutation increased sensitivity to AKT... PIK3CA PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
Among 33 patients treated with pan-AKT inhibitor M... KRAS KRAS p.Gly12Asp (p.G12D)
( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Asp (p.G12D)
( ENST00000692768.1, ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000693229.1 ) 		Sensitivity true CIViC Evidence detail
Among 33 patients treated with pan-AKT inhibitor M... PTEN PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT01480154 Active, not recruiting Phase 1 Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer November 23, 2011 March 7, 2025
NCT01251861 Active, not recruiting Phase 2 Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer December 23, 2010 March 7, 2025
NCT01658943 Completed Phase 2 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy August 2012 June 2015
NCT01253447 Completed Phase 2 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia October 2010 April 2014
NCT01258998 Completed Phase 2 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma December 2010 August 2015
NCT01783171 Completed Phase 1 Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery January 15, 2013 July 12, 2016
NCT01802320 Completed Phase 2 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery March 2013 August 5, 2015
NCT01260701 Completed Phase 2 Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer January 2011 July 2015
NCT01263145 Completed Phase 1 MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer January 5, 2011 October 19, 2012
NCT01277757 Completed Phase 2 Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer March 2011 August 2014
NCT01245205 Completed Phase 1 Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer November 2010
NCT01283035 Completed Phase 2 A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer April 2011 December 2014
NCT01294306 Completed Phase 2 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy February 2011 August 2015
NCT01307631 Completed Phase 2 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer March 2011 September 18, 2015
NCT01231919 Completed Phase 1 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia January 2011
NCT01344031 Completed Phase 1 MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer April 21, 2011
NCT01349933 Completed Phase 2 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer April 2011 October 2013
NCT01369849 Completed Phase 1/Phase 2 Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma September 2011 February 2014
NCT01425879 Completed Phase 2 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery April 2011 May 2014
NCT01481129 Completed Phase 2 Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma December 2011 June 2014
NCT01604772 Completed Phase 2 Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma July 23, 2012 November 22, 2014
NCT01319539 Terminated Phase 2 MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer April 2011 July 2013
NCT01239342 Terminated Phase 2 Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer January 27, 2011 September 19, 2018
NCT01239355 Terminated Phase 2 MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy December 2010 February 2013
NCT01281163 Terminated Phase 1 Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer January 2011 December 2013
NCT01519427 Terminated Phase 2 Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib January 2012 May 2013
NCT01705340 Terminated Phase 1 Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery September 2012
NCT01776008 Terminated Phase 2 Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer January 2013 May 5, 2015
NCT01859182 Withdrawn Phase 2 Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery January 2013 May 2013